Latest News – Page 1225 – Philippine Endourological Society

UncategorizedOctober 3, 2019

R2810-ONC-16XX: A Phase 1 Neoadjuvant Study of Stereotactic Body Radiation Therapy With Systemic REGN2810 and Intraprostatic Ipilimumab, Alone or in Combination, in Patients With Locally Advanced Prostate Cancer Prior to Radical Prostatectomy

R2810-ONC-16XX: A Phase 1 Neoadjuvant Study of Stereotactic Body Radiation Therapy With Systemic REGN2810 and Intraprostatic Ipilimumab, Alone or in Combination, in Patients With Locally Advanced Prostate Cancer Prior to Radical Prostatectomy Condition: Stage III Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIIB Prostate Cancer, Stage IIIC Prostate Cancer, Stage IV Prostate Cancer, Stage IVA […]

UncategorizedOctober 3, 2019

Open-label Clinical Study to Assess the Safety and Adequacy of Effectiveness of the SpectraCure P18 System (Interstitial Multiple Diode Lasers and IDOSE® Software) and Verteporfin for Injection (VFI) for the Treatment of Recurrent Prostate Cancer

Open-label Clinical Study to Assess the Safety and Adequacy of Effectiveness of the SpectraCure P18 System (Interstitial Multiple Diode Lasers and IDOSE® Software) and Verteporfin for Injection (VFI) for the Treatment of Recurrent Prostate Cancer Condition: Recurrent Prostate Cancer Intervention: Drug: Verteporfin Device: SpectraCure P18 System Purpose: The rationale for the study is to obtain […]

Robotic Assisted Urologic LaparoscopyOctober 3, 2019

Robotic partial nephrectomy versus radical nephrectomy in elderly patients with large renal masses.

Recent evidence suggests that the “oldest old” patients might benefit of partial nephrectomy (PN), but decisionmaking for this subset of patients is still controversial. Aim of this study is to compare outcomes of robotic partial (RPN) or radical nephrectomy (RRN) for large renal masses in patients older than 65 years.

UncategorizedOctober 3, 2019

How Cancer-specific Mortality Changes over Time after Radical Cystectomy: Conditional Survival of Patients with Nonmetastatic Urothelial Carcinoma of the Urinary Bladder – Beyond the Abstract

Conditional survival represents the adjustment in the probability of survival that is defined according to the duration of event-free follow-up. Since it dynamically accounts for changes in the risk of death over time, conditional survival may be more specific than unadjusted survival, especially in patients with event-free follow-up of several years. In this study, we […]

UncategorizedOctober 3, 2019

ESMO 2019: Overall Survival Interim Analysis Results of the Phase 3 SPARTAN Trial

Barcelona, Spain (UroToday.com) The randomized, phase 3 SPARTAN trial showed that apalutamide offered a metastasis-free survival (MFS) benefit over placebo for patients with non-metastatic (M0) castration-resistant prostate cancer (CRPC) with higher risk characteristics defined as PSA doubling time < or = 10 months prior to entry on the trial.1 This led to regulatory approval for apalutamide […]

UncategorizedOctober 3, 2019

ESMO 2019: Invited Discussant (LBA13) – The CARD Trial, A Randomized, Open-Label Study of Cabazitaxel vs Abiraterone or Enzalutamide in mCRPC

Barcelona, Spain (UroToday.com) Dr. De Wit’s presentation of the positive CARD trial, Dr. Silke Gillessen provided an invited discussion regarding the implications and practice-changing measures that result from these findings. Dr. Gillessen notes that currently, we have several agents for metastatic castration-resistant prostate cancer (mCRPC) patients with overall survival (OS) benefit, including: abiraterone, cabazitaxel, docetaxel, enzalutamide, radium-223, […]

UncategorizedOctober 3, 2019

ESMO 2019: Invited Discussant: IMvigor130: Phase III Study of Atezolizumab with or without Platinum-Based Chemotherapy in Previously Untreated Metastatic Urothelial Carcinoma

Barcelona, Spain (UroToday.com) Atezolizumab has received regulatory approval for patients with locally advanced or metastatic urothelial carcinoma. This has occurred for both cisplatin-ineligible patients in the first-line setting and also for those in the post-platinum treated setting.1, 2 In other malignancies, such as lung cancer, major advances have been made in treatment outcomes when cytotoxic […]

UncategorizedOctober 3, 2019

ESMO 2019: EV-103 Enfortumab Vedotin plus Pembrolizumab for Urothelial Carcinoma

Barcelona, Spain (UroToday.com) Recently, we’ve seen some major advances for patients with locally advanced and metastatic urothelial carcinoma. For instance, pembrolizumab, an anti-PD-1 antibody has received regulatory approval for both cisplatin ineligible patients in the first-line setting and also in the post-platinum treated population.1, 2 Enfortumab vedotin is a novel antibody drug conjugate, targeting Nectin-4, […]

UncategorizedOctober 3, 2019

ESMO 2019: Invited Discussant: Testicular and Kidney Cancer (913PD – APACHE (Testicular), 914PD (Testicular) , and 915PD (RCC))

Barcelona, Spain (UroToday.com) Dr. Christian Kollmannsberger from the British Columbia Cancer Agency discussed three abstracts at the ESMO 2019 poster discussion: 913PD – APACHE: an open label, randomized, phase 2 study of Durvalumab, alone or in combination with Tremelimumab, in patients with refractory germ cell tumors: results from the expanded combination therapy cohort, 914PD – Prognostic […]

UncategorizedOctober 2, 2019

ESMO 2019: Prognostic Factors in Metastatic Seminomatous Germ Cell Tumors and Elevated HCG – a Study of the G3

Barcelona, Spain (UroToday.com) Seminomas do not express specific tumor markers, but in ∼20% of patients, serum HCG levels are elevated. The prognostic role of different marker levels at first diagnosis has not been thoroughly assessed. The objective of the current study was to assess prognostic factors in HCG positive seminoma patients. A presentation from Dr. […]

1
2
3
…
1,222
1,223
1,224
1,225
1,226
1,227
1,228
…
1,440
1,441
1,442